THE MCMANUS GROUP

Lobbying for ARDELYX · BioPharma Company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Oct 20, 2025

Lobbying activity 1

Medicare/Medicaid

Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.